EA027991B1 - Ноотропное средство "пантокальцин" в жидкой форме - Google Patents
Ноотропное средство "пантокальцин" в жидкой форме Download PDFInfo
- Publication number
- EA027991B1 EA027991B1 EA201691206A EA201691206A EA027991B1 EA 027991 B1 EA027991 B1 EA 027991B1 EA 201691206 A EA201691206 A EA 201691206A EA 201691206 A EA201691206 A EA 201691206A EA 027991 B1 EA027991 B1 EA 027991B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- drug
- acid
- liquid form
- trilon
- pantocalcin
- Prior art date
Links
- 229950001260 hopantenic acid Drugs 0.000 title claims description 23
- SBBDHANTMHIRGW-QMMMGPOBSA-N hopantenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCC(O)=O SBBDHANTMHIRGW-QMMMGPOBSA-N 0.000 title claims description 18
- 239000007788 liquid Substances 0.000 title abstract description 11
- 239000002664 nootropic agent Substances 0.000 title description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 239000000126 substance Substances 0.000 claims abstract description 11
- 230000001777 nootropic effect Effects 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 13
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 12
- 239000005711 Benzoic acid Substances 0.000 claims description 6
- 235000010233 benzoic acid Nutrition 0.000 claims description 6
- 159000000007 calcium salts Chemical class 0.000 claims description 6
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 claims description 5
- 239000007968 orange flavor Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- -1 hopantenic acid calcium salt Chemical class 0.000 claims description 4
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 4
- 239000008297 liquid dosage form Substances 0.000 claims description 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 35
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract description 16
- 239000013543 active substance Substances 0.000 abstract description 9
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 abstract description 8
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract description 8
- 230000000694 effects Effects 0.000 abstract description 4
- 238000002360 preparation method Methods 0.000 abstract description 3
- 239000008177 pharmaceutical agent Substances 0.000 abstract description 2
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 33
- OVXZVDMCQPLHIY-QXGOIDDHSA-L calcium;4-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O OVXZVDMCQPLHIY-QXGOIDDHSA-L 0.000 description 10
- 239000000203 mixture Substances 0.000 description 7
- 208000036626 Mental retardation Diseases 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000006188 syrup Substances 0.000 description 6
- 235000020357 syrup Nutrition 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 5
- 235000019640 taste Nutrition 0.000 description 5
- 235000019658 bitter taste Nutrition 0.000 description 4
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 4
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 206010013911 Dysgeusia Diseases 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 102000013830 Calcium-Sensing Receptors Human genes 0.000 description 2
- 108010050543 Calcium-Sensing Receptors Proteins 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 201000006347 Intellectual Disability Diseases 0.000 description 2
- 241000209140 Triticum Species 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- JBNULYRBVMNPIS-OWJCAWTQSA-L calcium;4-[[(2r)-2,4-dihydroxy-3,3-dimethylbutanoyl]amino]butanoate;hydrate Chemical compound O.[Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCCC([O-])=O JBNULYRBVMNPIS-OWJCAWTQSA-L 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 2
- 239000001095 magnesium carbonate Substances 0.000 description 2
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- YIRJTBYMOSPXPR-UHFFFAOYSA-K C(C1=CC=CC=C1)(=O)[O-].[Na+].[Ca+2].C(C1=CC=CC=C1)(=O)[O-].C(C1=CC=CC=C1)(=O)[O-] Chemical compound C(C1=CC=CC=C1)(=O)[O-].[Na+].[Ca+2].C(C1=CC=CC=C1)(=O)[O-].C(C1=CC=CC=C1)(=O)[O-] YIRJTBYMOSPXPR-UHFFFAOYSA-K 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000001253 Diurnal Enuresis Diseases 0.000 description 1
- 208000008967 Enuresis Diseases 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 208000028938 Urination disease Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 229940125681 anticonvulsant agent Drugs 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 230000002920 convulsive effect Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- General Preparation And Processing Of Foods (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2014101564/15A RU2542419C1 (ru) | 2014-01-20 | 2014-01-20 | Ноотропное средсто "пантокальцин" в жидкой форме |
| PCT/RU2015/000014 WO2015108449A1 (ru) | 2014-01-20 | 2015-01-16 | Ноотропное средство "пантокальцин" в жидкой форме |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201691206A1 EA201691206A1 (ru) | 2016-09-30 |
| EA027991B1 true EA027991B1 (ru) | 2017-09-29 |
Family
ID=53289006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201691206A EA027991B1 (ru) | 2014-01-20 | 2015-01-16 | Ноотропное средство "пантокальцин" в жидкой форме |
Country Status (6)
| Country | Link |
|---|---|
| CN (1) | CN105979931A (zh) |
| EA (1) | EA027991B1 (zh) |
| MY (1) | MY180331A (zh) |
| RU (1) | RU2542419C1 (zh) |
| UA (1) | UA113822C2 (zh) |
| WO (1) | WO2015108449A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2703293C1 (ru) * | 2018-11-06 | 2019-10-16 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Жидкая лекарственная форма для перорального введения, обладающая ноотропной активностью |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145213C1 (ru) * | 1999-05-25 | 2000-02-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая ноотропным действием, и способ ее получения |
| RU2177783C1 (ru) * | 2001-02-02 | 2002-01-10 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Ноотропное средство |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2181757C2 (ru) * | 2000-03-07 | 2002-04-27 | Тюменская государственная медицинская академия | Состав для стабилизации липидов |
| JP5271081B2 (ja) * | 2006-07-26 | 2013-08-21 | 旭化成ケミカルズ株式会社 | 球形素顆粒およびその製造方法 |
-
2014
- 2014-01-20 RU RU2014101564/15A patent/RU2542419C1/ru active
-
2015
- 2015-01-16 MY MYPI2016001359A patent/MY180331A/en unknown
- 2015-01-16 UA UAA201607849A patent/UA113822C2/uk unknown
- 2015-01-16 EA EA201691206A patent/EA027991B1/ru unknown
- 2015-01-16 WO PCT/RU2015/000014 patent/WO2015108449A1/ru active Application Filing
- 2015-01-16 CN CN201580005035.7A patent/CN105979931A/zh active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2145213C1 (ru) * | 1999-05-25 | 2000-02-10 | Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" | Фармацевтическая композиция, обладающая ноотропным действием, и способ ее получения |
| RU2177783C1 (ru) * | 2001-02-02 | 2002-01-10 | Общество С Ограниченной Ответственностью "Консорциум-Пик" | Ноотропное средство |
Non-Patent Citations (1)
| Title |
|---|
| МАСЛОВА О.И. и др. Эффективность применения препарата Пантогам сироп 10% (гопантеновая кислота) в коррекции когнитивных расстройств у детей. Вопросы современной педиатрии, 2004, том 3, № 4, с. 2-6 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MY180331A (en) | 2020-11-28 |
| CN105979931A (zh) | 2016-09-28 |
| WO2015108449A1 (ru) | 2015-07-23 |
| EA201691206A1 (ru) | 2016-09-30 |
| RU2542419C1 (ru) | 2015-02-20 |
| UA113822C2 (xx) | 2017-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2832506T3 (es) | Composiciones que comprenden ribósido de nicotinamida y una urolitina | |
| US11771733B2 (en) | Lisinopril formulations | |
| ES2450615T3 (es) | Composiciones que comprenden Tramadol y Celecoxib para el tratamiento del dolor | |
| ES2691309T3 (es) | Soluciones orales estables para API combinados | |
| EP3003384B1 (en) | Oral solution comprising atomoxetine hydrochloride | |
| JP3162709B2 (ja) | 抗ストレス、ストレス予防性及び向神経性作用の医薬調製物 | |
| RU2542419C1 (ru) | Ноотропное средсто "пантокальцин" в жидкой форме | |
| JPH0344324A (ja) | 性機能賦活剤 | |
| CN114432309A (zh) | 一种提高烟酰胺磷酸核糖转移酶活性的方法及其组合物 | |
| IL276838A (en) | Oral formulation and suspension of an oncology drug | |
| RU2177783C1 (ru) | Ноотропное средство | |
| CN111542314B (zh) | 神经退行性疾病的治疗剂 | |
| RU2396076C1 (ru) | Средство, уменьшающее степень острой алкогольной интоксикации (опьянения) и обладающее антипохмельным действием, биологически активная добавка, фармацевтическая композиция, лекарственное средство и способ получения | |
| JP2015199686A (ja) | 睡眠改善剤 | |
| JP6533784B2 (ja) | 眼の疲れ改善剤 | |
| CN111096948A (zh) | 一种拉科酰胺口服液及其制备方法 | |
| RU2546300C1 (ru) | Композиция, обладающая действием на центральную нервную систему и ее применение | |
| CN114786668B (zh) | 用于治疗抑郁症的环丝氨酸和锂的组合疗法 | |
| WO2017137767A1 (en) | Anti-neurodegenerative disease formulation containing apocynin and paeonol | |
| JP7371851B2 (ja) | 肉体的疲労及び疲労感を予防又は改善するオレアナン型トリテルペンを含有する組成物 | |
| US20150258197A1 (en) | Eutectic isometheptene mucate | |
| ES2864669T3 (es) | Agente profiláctico y terapéutico para el trastorno por déficit de atención/hiperactividad | |
| CN100560582C (zh) | 哌啶基吡唑类化合物及其制法和应用 | |
| Singh et al. | A REVIEW ON DIFFERENT FORMULATIONS OF BACLOFEN FOR SPASTICITY | |
| Manasa | Experimental evaluation of anticonvulsant activity of Hydrocotyle asiatica linn (Centella asiatica) in Albino mice |